Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Ohio for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Ohio only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Ohio (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stephanie Melton (NPI 1831721257)

Field	Value
Entity Type	Individual
Organization	Stephanie Melton
Address	3700 Park East Dr Ste 450
City	Beachwood
State	OH
ZIP	44122
Taxonomy	Family Nurse Practitioner
NPI Enumerated	February 5, 2020

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

Medicare revenue is highly concentrated: the provider reports $1.8M in total Medicare revenue and the precomputed top-3 share shows the three highest-revenue codes account for 86.0% of that Medicare revenue. Those top drivers are J1569 ($781.9K, 42.1% of Medicare revenue), J3245 ($528K, 28.5%), and J3111 ($285.6K, 15.4%), indicating a small set of products dominate receipts. This concentration is an essential context for any payer or competitive risk analysis.

The code mix indicates a specialty, infusion- and injection-focused practice rather than a general primary-care billing pattern: the largest revenue items are biologic/specialty injectable drugs (J1569 immune globulin, J3245 tildrakizumab, J3111 romosozumab) and the portfolio includes multiple infusion/administration codes (e.g., 96365, 96366, 96372). These codes suggest the provider operates an office- or clinic-based administration model for high-cost parenteral therapies and chronic biologic treatments rather than primarily evaluation-and-management visits.

This provider is effectively a single-payer Medicare biller: lifetime Medicare revenue is $1.8M while there is no Medicaid billing on file, so Medicaid contributes $0 in the available data. For analyses that depend on payer diversification, treat this entity as Medicare-dependent and evaluate policy or coverage changes at the Medicare level accordingly.

Competitive standing is uneven across the provider's top drugs. For J1569 the provider ranks #7 of 542 nationally (99th percentile) and is described as "notably above typical national volume for this code," signaling national-level leadership for that product; J3111 ranks #130 of 970 (87th percentile) which is a strong national position as well, while J3245 ranks #72 of 225 (67th percentile), a middle-tier national volume for that code. These ranks imply the provider is a dominant supplier for at least one high-value drug (J1569) and a meaningful participant for additional specialty biologics.

Administration and infusion activity is disproportionately high relative to national peers for several procedure codes, consistent with an infusion-centric workflow: 96366 ranks #116 of 2976 (96th percentile; notably above typical national volume for this code) and 96372 ranks #785 of 58224 (99th percentile; notably above typical national volume for this code). Even 96365 is at a high relative position (#475 of 8873, 95th percentile) though labeled "typical, unremarkable volume," together these administration-code percentiles point to above-average throughput of injectable/infusion sessions.

The provider's NPI tenure is relatively recent—enumerated 2020-02-05 (~6 years ago)—yet the revenue and high-percentile ranks for several codes indicate rapid build-up of a specialty infusible drug practice in that window. Tenure plus concentration suggests growth focused on a narrow set of biologic therapies rather than a long-standing, broadly diversified clinic footprint.

Revenue concentration in a handful of high-cost biologic drugs creates exposure to changes in product utilization, procurement, or Medicare policy: with J1569 alone accounting for $781.9K (42.1% of Medicare revenue) and the top three codes making up 86.0% of Medicare receipts, any formulary, reimbursement, or supply disruptions for those specific agents could materially affect this provider's Medicare revenue. Analysts should flag these codes for sensitivity analysis when modeling revenue risk or negotiating network participation.

Ancillary and supportive services appear present but negligible to revenue: low-fee items such as 36415 ($888), 96413 ($4K), and 96415 ($666) are reported but account for a very small share of Medicare receipts. This pattern reinforces that the business model centers on drug administration revenue rather than diagnostic testing or standalone procedures.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

12 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	21,720	$40	$781.9K
J3245	Injection, tildrakizumab, 1 mg	4,800	$110	$528K
J3111	Injection, romosozumab-aqqg, 1 mg	35,700	$10	$285.6K
J1306	Injection, inclisiran, 1 mg	13,630	$10	$122.7K
J0897	Injection, denosumab, 1 mg	5,520	$20	$99.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	450	$40	$17.7K
96366	The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease.	640	$10	$8.3K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	740	$10	$5.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	50	$80	$4K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	110	$10	$890

Showing 1–10 of 12

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Ohio Distribution

Stephanie Melton — 4 of 12 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Ohio

Full comparison — all codes billed, vs. state median

12 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3245	4	10	3,300	$110	$431.5K
J3111	5	20	15,540	$10	$246.6K
J1569	1	20	4,900	$40	$203.8K
J1306	4	10	7,380	$10	$83.4K
J0897	51	230	2,880	$20	$79.5K
96413	145	210	130	$90	$16.8K
36415	843	1,910	90	$10	$5.4K
96365	6	240	60	$40	$4.6K
96366	3	70	90	$10	$2.3K
96415	108	130	60	$20	$1.9K

Showing 1–10 of 12

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stephanie Melton, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jody Huss	OH	Acute Care Nurse Practitioner	$1.9M	$2.2K
Hailey Brogan	OH	Family Nurse Practitioner	$505K	$0
Gordon Myers	OH	Allergy & Immunology Physician	$251.2K	$0
Andrew Lazar	OH	Nephrology Physician	$175.1K	$0
Tambert Whetsel	OH	Gerontology Nurse Practitioner	$142K	$0
Donald Mcneil	OH	Allergy & Immunology Physician	$59K	$0

Nearby Providers

Other providers in the same ZIP code as Stephanie Melton, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Primary Care Practices Inc	OH	Internal Medicine Physician	$0	$78.7M
Pearl's Hope, LLC	OH	Home Health Agency	$0	$47.8M
Health Care Bridge, Inc	OH	Home Health Agency	$0	$32.3M
Cleveland Clinic Health System - East Region	OH	General Acute Care Hospital	$0	$31.5M
Altimate Care LLC	OH	Home Health Agency	$0	$24M
Signature Health, Inc	OH	Federally Qualified Health Center (FQHC)	$0	$23M
University Hospitals Ahuja Medical Center, Inc	OH	General Acute Care Hospital	$0	$21.1M
Shaker Clinic, LLC	OH	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$15.5M
Psychological & Behavioral Consultants, LLC	OH	Psychiatry Physician	$0	$14.9M
Northeast Home Health Services	OH	Home Health Agency	$0	$11.9M

Stephanie Melton — Billing Profile & Reimbursement Data

Sign up for Stephanie Melton — Billing Profile & Reimbursement Data policy alerts

Stephanie Melton — Billing Profile & Reimbursement Data

Sign up for Stephanie Melton — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References